Namma Clinic inaugurated in Ballari
Speaking at the event, Mr. Reddy said that the purpose of the Namma Clinic initiative is to offer quality healthcare services to people in their neighbourhood.
'People should not have to travel long distances for basic health care. These clinics will provide free and accessible health care to local residents, especially those from low-income backgrounds,' he said.
Mr. Reddy also announced that a well-equipped hospital with an investment of ₹5 crore will soon be built in the colony.
The clinic has been set up under the joint initiative of the district administration, the Zilla Panchayat, the District Health and Family Welfare Department and the Ballari City Corporation.
District Health and Family Welfare Officer Yalla Ramesh Babu stated that 12 Namma Clinics were sanctioned for Ballari district in 2023-24.
For 2024-25, another eight, six for Ballari city, one for Siruguppa and one for Kampli, have been approved bringing the total to 20 clinics in the district.
'Each clinic will serve a population of 10,000 to 20,000 and will be manned by a doctor, a nurse, a lab technician and Group D staff,' he explained.
Alongside the Karimaremmana Colony facility, clinics were also inaugurated at Srirampura Colony and APMC Yard area the same day.
Public response
Chandrakala, a resident of Karimaremmana Colony, said: 'Earlier, we had to visit health centres far away for even minor health issues. Having this clinic in our locality is a big relief. I thank the government for this initiative.'
Another resident, Chandini, noted, 'This building remained unused for many days. We are happy that it is now serving a useful purpose.'
Corporation council member Minchu Srinivas, District Surgeon N. Basareddy, RCH Officer Hanumanthappa, District Surveillance Officer Mariyambi, Leprosy Officer Veerendra Kumar, TB Officer Indrani and Health Education Officer Khurshid Begum were present, along with staff from the clinics and members of the public.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
20 hours ago
- News18
Missed Scans To Timely Diagnoses: How AI Is Changing Lung Cancer Care In India
Last Updated: Lung cancer cases are often diagnosed late at advanced stages. With the rise of AI in medicine, early intervention is now possible. For years, lung cancer has been one of the deadliest diagnoses, often caught too late, and treated with few options. In India, a majority of lung cancer cases are diagnosed at advanced stages, making early intervention the exception, not the norm. But now, that tide is beginning to turn, and AI is at the forefront of this transformation. 'AI is helping India move from late-stage panic to early-stage preparedness," says Bhargava Reddy, Chief Business Officer, Oncology at 'It's no longer futuristic, it's working on the ground today," he adds. Most lung cancer cases show no symptoms in the early stages. By the time patients experience breathlessness or persistent coughing, the disease is often advanced. And with a radiologist shortage and fragmented systems, delays are built in. 'Only 3.5%–7.2% of patients are diagnosed early. The rest come in when treatment windows are already shrinking," Reddy adds. AI's Game-Changing Role in Early Diagnosis Of Lung Cancer AI doesn't just interpret scans quickly; it catches abnormalities often missed in early assessments. 'AI's ability to find subtle signs, sometimes before symptoms appear, reshapes the timeline of care entirely," says Reddy. And it's not limited to expensive CTs. AI can scan routine chest X-rays, making advanced detection possible even in rural or under-resourced areas. Screening Made Scalable In India, where LDCT is neither affordable nor accessible for the masses, AI is turning the humble X-ray into a powerful tool. A common misconception is that AI is a tool reserved for high-tech hospitals. In reality, its most transformative impact is unfolding in primary health centres and rural clinics that have long struggled with limited access to specialist care. AI serves as a virtual assistant, helping frontline providers in under-resourced districts detect early signs of lung abnormalities, even without an on-site radiologist. This levels the playing field, enabling timely diagnosis where it was previously out of reach. In states like Goa, AI is already integrated into 11 public health centres, helping screen high-risk populations like smokers and those exposed to urban pollution. 'This is where AI is most transformative, not in high-tech hospitals, but in clinics that never had specialist access," Reddy notes. The WHO has already endorsed AI-supported chest X-ray screening. The next step? Embedding it into national cancer programs. 'Mainstreaming AI as essential, not optional, will be key to delivering timely, data-driven care," says Reddy. AI is not just enhancing lung cancer detection; it's changing when and how we act. By enabling earlier diagnosis, broader reach, and faster decision-making, AI is helping India move from late-stage panic to early-stage preparedness. view comments First Published: August 01, 2025, 13:13 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Economic Times
2 days ago
- Economic Times
Obesity drugs gain weight in labs: Several clinical trials by big and small pharma cos underway
Mumbai: As blockbuster weight-loss drugs Wegovy (semaglutide) and Mounjaro (tirzepatide) reap billions of dollars on hysteric demand for innovators Novo Nordisk and Eli Lilly, more pharma companies — big and small — are racing to join the frenzy. As many as 170 new anti-obesity drugs are in various stages of development — from preclinical evaluation to advanced trials — though medical experts advise caution against their harmful effects due to reckless self-medication. Data collated from the obesity drugs tracker of Stat News, a popular Boston-based website on medical and healthcare analytical and investigative news, show Amgen, AstraZeneca, Boehringer Ingelheim, Roche and Regeneron are among the big names that are part of the choking pipeline. However, giants like Swiss drug maker Novartis and UK-based GSK are taking a cautious view of the opportunity. Pfizer had a setback recently with its experimental pill danuglipron that resulted in liver injury in a patient during the clinical trials. Eli Lilly, which is seeing record-shattering sales, with its Zepbound/Mounjaro brands, has at least nine drugs listed in active research. Its Danish rival Novo Nordisk is working on 14 leads, including additional studies on the already approved products. In a mailed response to ET, an Eli Lilly India spokesperson said the company invests approximately 25% of its revenue in R&D, significantly exceeding industry benchmarks. 'We are strategically focusing on areas of high unmet need, such as obesity, a chronic disease that requires more effective treatment options. Our goal is to modernise how this disease is approached, and we are making bold, science-driven decisions to explore new treatment modalities,' she said. Referring to orforglipron, its nonpeptide, oral GLP-1 receptor agonist being studied for the treatment of obesity and type-2 diabetes, the Lilly spokesperson said, 'We've seen so far, we have a high degree of confidence on what this molecule could mean for patients.' But several drugs on the Stat News tracker are once-a-week injectables with the sole exception of San Diego-based Skye Bioscience, which is developing a once a-month injectable drug. Interestingly, like orforglipron, at least 64 drugs being developed are in the oral or pill form, marking a shift that will make dosing compliance easier and result in lower manufacturing costs than the injectables. A growing number of Chinese companies including Innovent, Sciwind, Zhejiang Doer, Innogen and Jiangsu Hengrui are catching up with their western counterparts on the back of speedy trials and conducive regulatory pathways, while India's Sun Pharma is the only one from the country that is listed to develop its own molecule utreglutide in earlystages of clinical trials. The other big names from India such as Dr Reddy's, Biocon, Cipla and Torrent are developing copies of semaglutide, which is pending patent expiry early next year. FRONTLINE STRATEGY AGAINST NCDS Diabetologist and obesity expert Rajiv Kovil told ET that the emergence of powerful anti-obesity therapies is driving a fundamental shift in the treatment of non-communicable diseases (NCDs). Now, he says, obesity care is no longer an afterthought, it's becoming the frontline strategy against NCDs. Stat News data show the areas of research for obesity drugs is rapidly expanding beyond targeting the GLP-1 gut hormones. Currently multiple modalities are being approached like silencing certain genes using the RNA interference technology that may have a longer effect than the injectables. Another biologic pathway is to target amylin, a hormone secreted by pancreas and has a role in stomach emptying and reduced calorie intake, without causing nausea or muscle loss. Some of the research involves combining multiple targets like GLP-1/GIP and amylin analogues. The competitive landscape is expected to change as at least 10 drugs are in phase-III clinical trials, the stage before which regulatory agencies grant marketing approvals. Besides the benefits in weight loss, the new experiments on an array of conditions are underway. Those include MASH (metabolic dysfunction-associated steatohepatitis), cardiovascular disease (CVD), obstructive sleep apnea, neurological disorders like Alzheimer's disease, polycystic ovary syndrome (PCOS), chronic kidney disease (CKD), heart failures and arthritis.
The Hindu
24-07-2025
- The Hindu
Namma Clinic inaugurated in Ballari
Ballari City MLA Nara Bharath Reddy, who inaugurated a new Namma Clinic at Karimaremmana Colony in Ballari on Thursday, underlined its importance in delivering quality primary healthcare services to urban population, particularly the economically weaker sections. Speaking at the event, Mr. Reddy said that the purpose of the Namma Clinic initiative is to offer quality healthcare services to people in their neighbourhood. 'People should not have to travel long distances for basic health care. These clinics will provide free and accessible health care to local residents, especially those from low-income backgrounds,' he said. Mr. Reddy also announced that a well-equipped hospital with an investment of ₹5 crore will soon be built in the colony. The clinic has been set up under the joint initiative of the district administration, the Zilla Panchayat, the District Health and Family Welfare Department and the Ballari City Corporation. District Health and Family Welfare Officer Yalla Ramesh Babu stated that 12 Namma Clinics were sanctioned for Ballari district in 2023-24. For 2024-25, another eight, six for Ballari city, one for Siruguppa and one for Kampli, have been approved bringing the total to 20 clinics in the district. 'Each clinic will serve a population of 10,000 to 20,000 and will be manned by a doctor, a nurse, a lab technician and Group D staff,' he explained. Alongside the Karimaremmana Colony facility, clinics were also inaugurated at Srirampura Colony and APMC Yard area the same day. Public response Chandrakala, a resident of Karimaremmana Colony, said: 'Earlier, we had to visit health centres far away for even minor health issues. Having this clinic in our locality is a big relief. I thank the government for this initiative.' Another resident, Chandini, noted, 'This building remained unused for many days. We are happy that it is now serving a useful purpose.' Corporation council member Minchu Srinivas, District Surgeon N. Basareddy, RCH Officer Hanumanthappa, District Surveillance Officer Mariyambi, Leprosy Officer Veerendra Kumar, TB Officer Indrani and Health Education Officer Khurshid Begum were present, along with staff from the clinics and members of the public.
